Home » Newsletters » BioWorld Science

BioWorld Science

May 30, 2001

View Archived Issues

Licensing opportunity from NIH: human nuclear receptor corepressor gene

Antibodies that selectively detect human nestin protein available from NIH

Licensing opportunity from NIH: bispecific fusion proteins for HIV infection

Yamanouchi identifies ethenesulfonamide ETA antagonist with good selectivity and oral activity

Synthetic IFN-gamma-derived peptide delays rejection of vascularized skin allografts

New combination treatment for malaria launched in Europe

Novartis launches Foradil Aerolizer in the U.S.

European group develops new molecular modeling tools for H3 antagonists

Locally active estrogens useful for menopausal vaginal dyspareunia

Telik begins phase II trial of TLK-286 for treatment of ovarian cancer

Oxxon Pharmaccines begins melanoma pharmaccine trials

ISAtx-247 highlighted at Transplant 2001 as having potential advantages over ciclosporin

Company Profile: Galileo Laboratories

Prescient NeuroPharma establishes collaboration with CNRS

Recombinant AAT closer to obtaining orphan drug designation in E.U.

Favorable phase I data presented for Bay-43-9006 at ASCO

Solid dosage form of antibody for UC to be developed by KS Biomedix and MedPharm

Combination therapy containing IMC-C225 beneficial in cancer patients with limited options

Takeda's Ixense approved in Europe for ED

Company Profile: Consensus

MCH antagonists and their utility described by Takeda

Potent new PDE5 inhibitors designed by Pfizer group

Improvement in glucose tolerance and insulin secretion produced by Shionogi compounds

Quinazolinones and related compounds and use as local anesthetics

New CCR5 antagonists designed at Takeda as agents for HIV

New antifungal/antibacterial enediyne compounds

Welfide describes new research in the area of cytokine modulation

Inhibitors of 5-HT reuptake and potential therapeutic applications presented by ADIR

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...